Volume 13, Number 1, 1-8, DOI: 10.1046/j.1525-1497.1998.00001.x

Published in partnership with the

Logo

Smoking cessation among inner-city African Americans unsing the nicotine transdermal patch

Jasjit S. Ahluwalia, Sally E. Mcnagny and W. Scott Clark

View Related Documents

Abstract

OBJECTIVE: To determine the efficacy of the transdermal nicotine patch for smoking cessation in inner-city African Americans.
DESIGN: Double-blind, placebo-controlled, randomized trial.
SETTING: Outpatient in an inner-city hospital.
PATIENTS AND PARTICIPANTS: A computer-generated random numbers table with a block size set at 20 was used to randomize 410 patients to one of two study arms.
INTERVENTIONS: The transdermal nicotine patch for 10 weeks as an adjunct to brief counseling.
MEASUREMENTS AND MAIN RESULTS: Of the 410 patients randomized, mean age was 48 years, 65% were female, 41% had less than a high school education, 51% had an annual household income of less than $8,000, and the average number of cigarettes smoked per day was 20. Quit rates at 10 weeks were 21.5% (44/205) with the nicotine patch, and 13.7% (28/205) with the placebo patch (p=.03). At 6 months, quit rates were 17.1% (35/205) with the nicotine patch, and 11.7% (24/205) with the placebo patch (p=.08). After adjusting for baseline differences in age and educational attainment, differences remained significant at 10 weeks (p=.04), but were not significant at 6 months (p=.14). Compliance rates for return visits were 83%, 78%, 55%, and 52%, at 1, 2, 6, and 10 weeks, respectively.
CONCLUSIONS: The nicotine patch significantly improves short-term quit rates in inner-city African Americans who are interested in trying to quit smoking. Efforts should be made to reach underserved populations through smoking cessation programs, and to assist in maintaining abstinence.

Key words  smoking cessation - African Americans - innercity patients - nicotine patch

Presented in part at the annual meeting of the Society of General Internal Medicine, San Giego, Calif., May 6, 1995.
Supported by an American Cancer Society Career Development Award to Dr. Ahluwalia, an unrestricted grant from Marion Merrell Dow, Inc., and the Emory Medical Care Foundation.

Fulltext Preview

Image of the first page of the fulltext document